HCP
31
-5
ES
46
12
HRB
52
5
BF.B
57
6
GPS
37
4
AMT
30
9
BBBY
36
3
PFG
48
2
XEL
64
20
PPL
65
5
WM
65
6
EQIX
52
5
BMY
43
3
MCK
41
7
PG
58
3
HES
62
3
BAX
35
3
NFLX
51
3
APA
62
2
FOX
31
-4
HCP
31
-5
ES
46
12
HRB
52
5
BF.B
57
6
GPS
37
4
AMT
30
9
BBBY
36
3
PFG
48
2
XEL
64
20
PPL
65
5
WM
65
6
EQIX
52
5
BMY
43
3
MCK
41
7
PG
58
3
HES
62
3
BAX
35
3
NFLX
51
3
APA
62
2
FOX
31
-4
Financhill
Back

Sarepta Therapeutics 10K Form

Sell
47

SRPT
Sarepta Therapeutics

Last Price:
130.19
Seasonality Move:
15.81%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SRPT News And Ratings

See the #1 stock for the next 7 days that we like better than SRPT

SRPT Financial Statistics

Sales & Book Value

Annual Sales: $933.01M
Cash Flow: $-100.36M
Price / Cash Flow: 0
Annual Sales: $4.38
Price / Book: 29.76

Profitability

EPS (TTM): -8.03000
Net Income (TTM): $-703.49M
Gross Margin: $793.02M
Return on Equity: -105.72%
Return on Assets: -22.71%

Sarepta Therapeutics Earnings Forecast

Key Sarepta Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 27 years for SRPT is 85.00%.
  • The Selling, General & Administrative Expenses for SRPT have been equal to 48.38% of Gross Profit Margin.
  • The Research & Development expenses have been 94.01% of Revenue.
  • The Interest Expense is -7.57% of Operating Income.
  • The Net Earning history of SRPT is -75.40% of Total Revenues.
  • Per Share Earnings over the last 27 years have been positive in 13 years.

Sarepta Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: SRPT
CUSIP: 803607
Website: sarepta.com

Debt

Debt-to-Equity Ratio: 4.01
Current Ratio: 4.13
Quick Ratio: 3.63

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 16.48

SRPT Technical Analysis vs Fundamental Analysis

Sell
47
Sarepta Therapeutics (SRPT) is a Sell

Is Sarepta Therapeutics a Buy or a Sell?